Efficient resource to therapy of complex disorders with minor side-effects has enhanced the growth of antibodies based therapeutics against chemical drugs.
Europe Antibodies Market was worth $ 31.78 Billion in 2018 and estimated to reach $ 54.55 Billion by the end of 2023 with a growing potential of 11.41 %.
Antibodies (Ab’s) are also known as an immunoglobulin (Ig) that are large, Y-shaped protein produced by plasma cells which are used by the immune system to detect, identify and neutralize pathogens such as Viruses and bacteria. The antibody recognizes harmful agent, called an antigen, via the Fab's variable region. Depending on the type of antigen, the binding may inhibit the biological process causing the disease or could activate macrophages to destroy the foreign substance.
Europe Antibodies market is driven by innovative products, increasing rate of adoption to therapeutic antibodies in cost-sensitive markets, rise in chronic illnesses due to population shift and increasing longevity, quick approval for breakthrough therapies by regulatory authorities, and adoption of diagnostic antibodies. High cost of treatment and side effects associated with antibodies treatment are the restraints that are affecting the growth of the market.
Based on product type, the market is segmented into Monoclonal Antibodies, Polyclonal Antibodies, and Anti-body drug complexes. The monoclonal antibodies are further segmented into Murine, Chimeric, Humanized, and Human. The polyclonal antibodies are further categorized into Type I, Type II, Type III, Type IV, Type V, Type VI, Type VII, Type VIII. The Antibody-Drug Complexes are further segmented into Immunogen Technology, Seattle Genetics Technology, and Immunomedics Technology.
Based on Indication, the market is segmented into Cancer, Auto immune diseases, Infectious diseases, cardiovascular diseases, and CNS disorders, others (Inflammatory, Microbial Diseases, & Other). Based on end users, the market is segmented into Hospitals/Clinics, Research institute, Diagnostics laboratories.
Based on Application, the market is segmented into Medical, Experimental. The Experimental segment is further categorized into Western blot, ELISA, Radioimmune Assays, immunofluorescence, others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry).Based on Geography, the Europe Antibodies market is analysed under various regions namely U.K, Germany, France, Italy and Spain.
Some of the Key players operating in Europe Antibodies market are Merck KGaA, Novartis AG, Pfizer Inc., ThermoFisher Scientific Inc., Eli Lilly and company, BioMerieux, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Qiagen N.V.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Monoclonal Antibodies
5.1.1.1 Murine
5.1.1.2 Chimeric
5.1.1.3 Humanized
5.1.1.4 Human
5.1.2 Polyclonal Antibodies
5.1.2.1 Type I
5.1.2.2 Type II
5.1.2.3 Type III
5.1.2.4 Type IV
5.1.2.5 Type V
5.1.2.6 Type VI
5.1.2.7 Type VII
5.1.2.8 Type VIII
5.1.3 Antibody-Drug Complexes
5.1.3.1 Immunogen Technology
5.1.3.2 Seattle Genetics Technology
5.1.3.3 Immunomedics Technology
5.2 By Indication
5.2.1 Cancer
5.2.2 Autoimmune Diseases
5.2.3 Infectious Diseases
5.2.4 Cardiovascular Diseases
5.2.5 CNS Disorders
5.2.6 Others (Inflammatory, Microbial Diseases, & Other)
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
5.4 Application
5.4.1 Medical
5.4.2 Experimental
5.4.2.1 Western Blot
5.4.2.2 ELISA
5.4.2.3 Radioimmune Assays
5.4.2.4 Immunofluorescence
5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)
6. Geographical Analysis
6.1 Europe
6.1.1 Introduction
6.1.2 U.K
6.1.3 Spain
6.1.4 Germany
6.1.5 Italy
6.1.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Merck KGaA (Germany)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 Thermo Fisher Scientific Inc. (U.S.)
9.5 Eli Lilly and Company (U.S.)
9.6 bioMerieux (France)
9.7 Bristol-Myers Squibb (U.S.)
9.9 F. Hoffmann-La Roche Ltd. (Switzerland)
9.10 Qiagen N.V. (Netherlands)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
